title: Method for novel anti-cancer drug development using tumor explants of surgical specimens.
abstract: The current therapies for malignant glioma have only palliative effect. For therapeutic development, one hurdle is the discrepancy of efficacy determined by current drug efficacy tests and the efficacy on patients. Thus, novel and reliable methods for evaluating drug efficacy are warranted in pre-clinical phase. In vitro culture of tumor tissues, including cell lines, has substantial phenotypic, genetic, and epigenetic alterations of cancer cells caused by artificial environment of cell culture, which may not reflect the biology of original tumors in situ. Xenograft models with the immunodeficient mice also have limitations, i.e., the lack of immune system and interspecies genetic and epigenetic discrepancies in microenvironment. Here, we demonstrate a novel method using the surgical specimens of malignant glioma as undissociated tumor blocks to evaluate treatment effects. To validate this method, data with the current first-line chemotherapeutic agent, temozolomide (TMZ), are described. We used the freshly-removed surgical specimen of malignant glioma for our experiments. We performed intratumoral injection of TMZ or other drug candidates, followed by incubation and analysis on surgical specimens. Here, we sought to establish a tumor tissue explant method as a platform to determine the efficacy of novel anti-cancer therapies so that we may be able to overcome, at least, some of the current limitations and fill the existing gap between the current experimental data and the efficacy on an actual patient's tumor. This method may have the potential to accelerate identifying novel chemotherapeutic agents for solid cancer treatment.
authors.affiliation: Department of Neurological Surgery, The Ohio State University Medical Center.
authors.forename: Kaushal
authors.initials: K
authors.lastname: Joshi
authors.forename: Habibe
authors.initials: H
authors.lastname: Demir
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Yamada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Abhik
authors.initials: A
authors.lastname: Ray-Chaudhury
authors.forename: Ichiro
authors.initials: I
authors.lastname: Nakano
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005434:Flow Cytometry / Q000379:methods; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D015552:Injections, Intralesional; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D003606:Dacarbazine; D000077204:Temozolomide